Tânia R.
- Country
- Portugal
- Department
- Oncology
Research Overview
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
- Evaluation of Tinzaparin Sodium for Venous Thromboembolism Prophylaxis in Patients with Metastatic Colorectal Cancer Initiating First-Line Systemic Therapy
- Phase 1/2 Study of Elraglusib (9-ING-41) as Monotherapy and in Combination with Chemotherapy in Refractory Hematologic Malignancies or Solid Tumors
Data & Insights
Has run more than one trial at 62 of 216 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating advanced gastric and gastroesophageal cancers, with particular focus on HER2-positive tumors and novel therapeutic approaches involving targeted antibody treatments.
- Esophageal Carcinoma Management
- Gastric Cancer Treatment
- GEJ Adenocarcinoma Therapy
The investigator works with innovative treatments including monoclonal antibodies and combination therapy approaches.
Colorectal Cancer Research
Expertise in managing metastatic colorectal cancer, with specific interest in preventive strategies for venous thromboembolic disease in advanced-stage patients.
- Stage IV Colorectal Management
- Thrombosis Prevention
- Systemic Treatment Protocols
Clinical work encompasses both therapeutic and prophylactic approaches in advanced colorectal disease.
Advanced Cancer Therapeutics
Focus on treating refractory solid tumors and exploring novel therapeutic combinations for patients with advanced malignancies.
- Pancreatic Cancer Treatment
- Hematologic Malignancies
- Investigational Drug Studies
The investigator evaluates innovative treatment approaches for patients with metastatic disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.